{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:31:13Z","timestamp":1792517473772,"version":"4.5.0"},"reference-count":31,"publisher":"National Academy of Sciences","issue":"47","license":[{"start":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T00:00:00Z","timestamp":1541548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"HHS | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM106990"],"award-info":[{"award-number":["GM106990"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2018,11,20]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>The development of selective antagonists for muscarinic acetylcholine receptors is challenging due to high homology in orthosteric binding sites among subtypes. Starting from a single amino acid difference in the orthosteric pockets in M2 muscarinic acetylcholine receptor (M2R) and M3R, we developed an M3R-selective antagonist using molecular docking and structure-based design. The resulting M3R antagonist showed up to 100-fold selectivity over the M2R in affinity and 1,000-fold selectivity in vivo. The docking-predicted geometry was further confirmed by a 3.1 \u00c5 crystal structure of M3R in complex with the selective antagonist. The potential of structure-based design to develop selective drugs with reduced off-target effects is supported by this study.<\/jats:p>","DOI":"10.1073\/pnas.1813988115","type":"journal-article","created":{"date-parts":[[2018,11,7]],"date-time":"2018-11-07T15:35:11Z","timestamp":1541604911000},"page":"12046-12050","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":92,"title":["Structure-guided development of selective M3 muscarinic acetylcholine receptor antagonists"],"prefix":"10.1073","volume":"115","author":[{"given":"Hongtao","family":"Liu","sequence":"first","affiliation":[{"name":"Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, 100084 Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefa","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91058 Erlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inbar","family":"Fish","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158;"},{"name":"Department of Biochemistry and Molecular Biology, George S. Wise Faculty of Life Sciences, Tel-Aviv University, 6997801 Ramat Aviv, Israel;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Schaake","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91058 Erlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Eitel","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91058 Erlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Bartuschat","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91058 Erlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Kaindl","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91058 Erlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannelore","family":"Rampp","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91058 Erlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashutosh","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91058 Erlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"H\u00fcbner","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91058 Erlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary J.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra G.","family":"Vincent","sequence":"additional","affiliation":[{"name":"Department of Biomedical &amp; Molecular Sciences, Queen\u2019s University, Kingston, ON, Canada K7L 3N6;"},{"name":"Division of Respirology, Department of Medicine, Queen\u2019s University, Kingston, ON, Canada K7L 3N6;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Biomedical &amp; Molecular Sciences, Queen\u2019s University, Kingston, ON, Canada K7L 3N6;"},{"name":"Division of Respirology, Department of Medicine, Queen\u2019s University, Kingston, ON, Canada K7L 3N6;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus R.","family":"Heinrich","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91058 Erlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Hirata","sequence":"additional","affiliation":[{"name":"Advanced Photon Technology Division, Research Infrastructure Group, SR Life Science Instrumentation Unit, RIKEN\/SPring-8 Center, 1-1-1 Kouto, Sayo-cho, Sayo-gun, Hyogo 679-5148, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, 100084 Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger K.","family":"Sunahara","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, CA 92093;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Shoichet","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K.","family":"Kobilka","sequence":"additional","affiliation":[{"name":"Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, 100084 Beijing, China;"},{"name":"Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Gmeiner","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Pharmacy, Medicinal Chemistry, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg, 91058 Erlangen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2018,11,7]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: New agents, targets and indications","volume":"16","author":"Hauser AS","year":"2017","unstructured":"AS Hauser, MM Attwood, M Rask-Andersen, HB Schi\u00f6th, DE Gloriam, Trends in GPCR drug discovery: New agents, targets and indications. Nat Rev Drug Discov 16, 829\u2013842 (2017).","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_4_2_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ejphar.2015.05.013","article-title":"Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs","volume":"763","author":"Lee S-M","year":"2015","unstructured":"S-M Lee, JM Booe, AA Pioszak, Structural insights into ligand recognition and selectivity for classes A, B, and C GPCRs. Eur J Pharmacol 763, 196\u2013205 (2015).","journal-title":"Eur J Pharmacol"},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1146\/annurev.pa.30.040190.003221","article-title":"Muscarinic receptor subtypes","volume":"30","author":"Hulme EC","year":"1990","unstructured":"EC Hulme, NJM Birdsall, NJ Buckley, Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol 30, 633\u2013673 (1990).","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"e_1_3_4_4_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1615\/CritRevNeurobiol.v10.i1.40","article-title":"Molecular biology of muscarinic acetylcholine receptors","volume":"10","author":"Wess J","year":"1996","unstructured":"J Wess, Molecular biology of muscarinic acetylcholine receptors. Crit Rev Neurobiol 10, 69\u201399 (1996).","journal-title":"Crit Rev Neurobiol"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0031-6997(24)01362-0","article-title":"International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors","volume":"50","author":"Caulfield MP","year":"1998","unstructured":"MP Caulfield, NJM Birdsall, International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50, 279\u2013290 (1998).","journal-title":"Pharmacol Rev"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrd4295","article-title":"Muscarinic acetylcholine receptors: Novel opportunities for drug development","volume":"13","author":"Kruse AC","year":"2014","unstructured":"AC Kruse, , Muscarinic acetylcholine receptors: Novel opportunities for drug development. Nat Rev Drug Discov 13, 549\u2013560 (2014).","journal-title":"Nat Rev Drug Discov"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0026-895X(25)10204-6","article-title":"Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: Radioligand binding and autoradiographic mapping","volume":"45","author":"Haddad EB","year":"1994","unstructured":"EB Haddad, JC Mak, PJ Barnes, Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: Radioligand binding and autoradiographic mapping. Mol Pharmacol 45, 899\u2013907 (1994).","journal-title":"Mol Pharmacol"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature10753","article-title":"Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist","volume":"482","author":"Haga K","year":"2012","unstructured":"K Haga, , Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482, 547\u2013551 (2012).","journal-title":"Nature"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature10867","article-title":"Structure and dynamics of the M3 muscarinic acetylcholine receptor","volume":"482","author":"Kruse AC","year":"2012","unstructured":"AC Kruse, , Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature 482, 552\u2013556 (2012).","journal-title":"Nature"},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature17188","article-title":"Crystal structures of the M1 and M4 muscarinic acetylcholine receptors","volume":"531","author":"Thal DM","year":"2016","unstructured":"DM Thal, , Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature 531, 335\u2013340 (2016).","journal-title":"Nature"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12735","article-title":"Activation and allosteric modulation of a muscarinic acetylcholine receptor","volume":"504","author":"Kruse AC","year":"2013","unstructured":"AC Kruse, , Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature 504, 101\u2013106 (2013).","journal-title":"Nature"},{"key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/acs.jmedchem.6b01453","article-title":"Recent advances in structure-based drug design targeting class A G protein-coupled receptors utilizing crystal structures and computational simulations","volume":"61","author":"Lee Y","year":"2018","unstructured":"Y Lee, S Basith, S Choi, Recent advances in structure-based drug design targeting class A G protein-coupled receptors utilizing crystal structures and computational simulations. J Med Chem 61, 1\u201346 (2018).","journal-title":"J Med Chem"},{"key":"e_1_3_4_13_2","first-page":"1","volume-title":"Progress in Medicinal Chemistry","author":"Congreve M","year":"2014","unstructured":"M Congreve, JM Dias, FH Marshall Progress in Medicinal Chemistry, eds G Lawton, DR Witty (Elsevier, Oxford) Vol 53, 1\u201363 (2014)."},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1021\/jm00402a035","article-title":"Affinity and selectivity of the optical isomers of 3-quinuclidinyl benzilate and related muscarinic antagonists","volume":"31","author":"Rzeszotarski WJ","year":"1988","unstructured":"WJ Rzeszotarski, , Affinity and selectivity of the optical isomers of 3-quinuclidinyl benzilate and related muscarinic antagonists. J Med Chem 31, 1463\u20131466 (1988).","journal-title":"J Med Chem"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"63S","DOI":"10.1378\/chest.117.2_suppl.63S","article-title":"The pharmacological properties of tiotropium","volume":"117","author":"Barnes PJ","year":"2000","unstructured":"PJ Barnes, The pharmacological properties of tiotropium. Chest 117, 63S\u201366S (2000).","journal-title":"Chest"},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"S2051","DOI":"10.1016\/j.arabjc.2013.07.035","article-title":"Biphenyls and their derivatives as synthetically and pharmacologically important aromatic structural moieties","volume":"10","author":"Jain ZJ","year":"2017","unstructured":"ZJ Jain, PS Gide, RS Kankate, Biphenyls and their derivatives as synthetically and pharmacologically important aromatic structural moieties. Arabian J Chem 10, S2051\u2013S2066 (2017).","journal-title":"Arabian J Chem"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1021\/jm501371s","article-title":"Organic carbamates in drug design and medicinal chemistry","volume":"58","author":"Ghosh AK","year":"2015","unstructured":"AK Ghosh, M Brindisi, Organic carbamates in drug design and medicinal chemistry. J Med Chem 58, 2895\u20132940 (2015).","journal-title":"J Med Chem"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1021\/jo500063r","article-title":"Oxidative radical arylation of anilines with arylhydrazines and dioxygen from air","volume":"79","author":"Hofmann J","year":"2014","unstructured":"J Hofmann, H Jasch, MR Heinrich, Oxidative radical arylation of anilines with arylhydrazines and dioxygen from air. J Org Chem 79, 2314\u20132320 (2014).","journal-title":"J Org Chem"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.1021\/acs.jmedchem.5b00258","article-title":"Applications of fluorine in medicinal chemistry","volume":"58","author":"Gillis EP","year":"2015","unstructured":"EP Gillis, KJ Eastman, MD Hill, DJ Donnelly, NA Meanwell, Applications of fluorine in medicinal chemistry. J Med Chem 58, 8315\u20138359 (2015).","journal-title":"J Med Chem"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1126\/science.1131943","article-title":"Fluorine in pharmaceuticals: Looking beyond intuition","volume":"317","author":"M\u00fcller K","year":"2007","unstructured":"K M\u00fcller, C Faeh, F Diederich, Fluorine in pharmaceuticals: Looking beyond intuition. Science 317, 1881\u20131886 (2007).","journal-title":"Science"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-2999(99)00439-2","article-title":"Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site","volume":"380","author":"Heitz F","year":"1999","unstructured":"F Heitz, , Site-directed mutagenesis of the putative human muscarinic M2 receptor binding site. Eur J Pharmacol 380, 183\u2013195 (1999).","journal-title":"Eur J Pharmacol"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1002\/j.1460-2075.1991.tb04941.x","article-title":"Site-directed mutagenesis of the m3 muscarinic receptor: Identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding","volume":"10","author":"Wess J","year":"1991","unstructured":"J Wess, D Gdula, MR Brann, Site-directed mutagenesis of the m3 muscarinic receptor: Identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding. EMBO J 10, 3729\u20133734 (1991).","journal-title":"EMBO J"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.str.2014.08.022","article-title":"Modified T4 lysozyme fusion proteins facilitate G protein-coupled receptor crystallogenesis","volume":"22","author":"Thorsen TS","year":"2014","unstructured":"TS Thorsen, R Matt, WI Weis, BK Kobilka, Modified T4 lysozyme fusion proteins facilitate G protein-coupled receptor crystallogenesis. Structure 22, 1657\u20131664 (2014).","journal-title":"Structure"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1248\/cpb.46.1286","article-title":"Selective muscarinic antagonists. II. Synthesis and antimuscarinic properties of biphenylylcarbamate derivatives","volume":"46","author":"Naito R","year":"1998","unstructured":"R Naito, , Selective muscarinic antagonists. II. Synthesis and antimuscarinic properties of biphenylylcarbamate derivatives. Chem Pharm Bull (Tokyo) 46, 1286\u20131294 (1998).","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1016\/j.bmcl.2011.03.096","article-title":"Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists","volume":"21","author":"Prat M","year":"2011","unstructured":"M Prat, , Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinyl carbamates as potent and long acting muscarinic antagonists. Bioorg Med Chem Lett 21, 3457\u20133461 (2011).","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_4_26_2","unstructured":"S Nagashima Patent PCT\/JP2008\/052189. (2008)."},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0024-3205(97)00047-7","article-title":"Discovery & development of selective M3 antagonists for clinical use","volume":"60","author":"Alabaster VA","year":"1997","unstructured":"VA Alabaster, Discovery & development of selective M3 antagonists for clinical use. Life Sci 60, 1053\u20131060 (1997).","journal-title":"Life Sci"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/004982598239768","article-title":"Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man","volume":"28","author":"Beaumont KC","year":"1998","unstructured":"KC Beaumont, NJ Cussans, DJ Nichols, DA Smith, Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man. Xenobiotica 28, 63\u201375 (1998).","journal-title":"Xenobiotica"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1124\/jpet.109.151639","article-title":"Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile","volume":"331","author":"Gavald\u00e0 A","year":"2009","unstructured":"A Gavald\u00e0, , Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 331, 740\u2013751 (2009).","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_4_30_2","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1021\/ci100214a","article-title":"Rapid context-dependent ligand desolvation in molecular docking","volume":"50","author":"Mysinger MM","year":"2010","unstructured":"MM Mysinger, BK Shoichet, Rapid context-dependent ligand desolvation in molecular docking. J Chem Inf Model 50, 1561\u20131573 (2010).","journal-title":"J Chem Inf Model"},{"key":"e_1_3_4_31_2","first-page":"125","article-title":"XDS","volume":"66","author":"Kabsch W","year":"2010","unstructured":"W Kabsch, XDS. Acta Cryst D66, 125\u2013132 (2010).","journal-title":"Acta Cryst"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.pnas.org\/syndication\/doi\/10.1073\/pnas.1813988115","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1813988115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:20:19Z","timestamp":1775262019000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1813988115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,7]]},"references-count":31,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2018,11,20]]}},"alternative-id":["10.1073\/pnas.1813988115"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1813988115","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,7]]},"assertion":[{"value":"2018-11-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}